Publications by Dr Tina Biss - ePrints

Browsing publications by Dr Tina Biss.

Newcastle Authors	Title	Year
Dr Tina Biss Dr Caroline Grayson	Haematological evaluation of bruising and bleeding in children undergoing child protection investigation for possible physical maltreatment: A British Society for Haematology Good Practice Paper	2022
Dr Emma Kampouraki Dr Peter Avery Dr Tina Biss Dr Hilary Wynne Professor Farhad Kamali et al.	Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients	2021
Dr Emma Kampouraki Dr Salah Abohelaika Dr Peter Avery Dr Tina Biss Dr Hilary Wynne et al.	Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing	2021
Dr Tina Biss	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)	2020
Dr Tina Biss	Severity and Features of Epistaxis in Children with a Mucocutaneous Bleeding Disorder	2018
Dr Tina Biss	Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura	2017
Dr Tina Biss	Challenges in adolescent venous thromboembolism	2016
Salah Abohelaika Dr Tina Biss Dr Hilary Wynne Professor Farhad Kamali	C0170: The Impact of Dietary Vitamin K on the Pharmacological Activity of FXa Inhibitor Rivaroxaban in Man	2014
Dr Tina Biss Professor Farhad Kamali	Characterizing variability in warfarin dose requirements in children using modelling and simulation	2014
Dr Tina Biss Bruce Jaffray	Risk Stratification for the Use of Thromboprophylaxis in Young People With IBD Requires Further Evaluation	2014
Salah Abohelaika Dr Tina Biss Dr Peter Murphy Professor Farhad Kamali	The impact of dietary vitamin K on the pharmacological activity of FXa inhibitor rivaroxaban in man	2014
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children	2013
Dr Tina Biss Dr Peter Avery Julian Leathart Professor Farhad Kamali	VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children	2012
Dr Tina Biss Professor Farhad Kamali	Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?	2012
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Warfarin dose prediction in children using pharmacogenetics information	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Professor Farhad Kamali	Warfarin dose prediction in children using pharmacogenetics information	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Dr John Hanley Professor Ann Daly et al.	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children	2011
Dr Tina Biss	-1 to+4 vs. 0 to+3?: comparing scoring systems for bleeding symptoms in the condensed mcmdm-1 VWD and the pediatric bleeding questionnaires	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal]	2011
Dr Tina Biss Professor Ashley Adamson Emeritus Professor Chris Seal Professor Farhad Kamali	The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Warfarin treatment outcomes in children monitored at home with a point-of-care device	2011
Dr Tina Biss	Evaluation of the Severity and Pattern of Epistaxis In Children with a Mucocutaneous Bleeding Disorder and In Healthy Children Using a Standardized Questionnaire	2010
Dr Tina Biss	Evaluation of Bleeding Symptoms in Children with An Inherited Mucocutaneous Bleeding Disorder	2009
Dr Tina Biss Dr Katherine Talks	Intracranial Haemorrhage in Patients with An Inherited Bleeding Disorder: A Review of 10 Years Experience in a UK Haemophilia Comprehensive Centre	2009
Dr Tina Biss Dr John Hanley	Use of recombinant factor VIIa (rFVIIa) in the management of intractable haemorrhage - A survey of current UK practice	2007
Dr Tina Biss Dr John Hanley	Clinical scoring systems to guide the use of recombinant activated factor VII (rFVIIa) in major haemorrhage	2006
Dr Tina Biss Dr Mark Velangi Dr John Hanley	Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature	2006
Dr Tina Biss Dr John Hanley	Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: Use of a clinical scoring system to predict outcome	2006
Dr Tina Biss Dr John Hanley Andrew Loughney	Recombinant activated factor VII in the management of major obstetric haemorrhage	2006
Dr Tina Biss Dr John Hanley	The use of recombinant factor VIIa in the management of major haemorrhage: Experience within the northern region of the UK	2005
Dr Tina Biss Dr Peter Hamilton	Myelofibrosis and angiodysplasia of the colon: another manifestation of portal hypertension and massive splenomegaly?	2004
Dr Tina Biss Dr Lucy Crossman Dr John Hanley	An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage	2003